Norden Group LLC Has $9.54 Million Position in Bristol Myers Squibb Company $BMY

Norden Group LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 816.1% during the 4th quarter, Holdings Channel reports. The firm owned 176,915 shares of the biopharmaceutical company’s stock after purchasing an additional 157,604 shares during the quarter. Bristol Myers Squibb makes up about 0.9% of Norden Group LLC’s investment portfolio, making the stock its 17th biggest position. Norden Group LLC’s holdings in Bristol Myers Squibb were worth $9,543,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in BMY. Regatta Capital Group LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $230,000. Olistico Wealth LLC acquired a new position in Bristol Myers Squibb in the fourth quarter valued at about $65,000. SeaCrest Wealth Management LLC grew its stake in Bristol Myers Squibb by 1.6% during the fourth quarter. SeaCrest Wealth Management LLC now owns 18,388 shares of the biopharmaceutical company’s stock worth $1,043,000 after buying an additional 294 shares during the last quarter. Benin Management CORP increased its holdings in shares of Bristol Myers Squibb by 12.4% during the fourth quarter. Benin Management CORP now owns 9,063 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 1,000 shares in the last quarter. Finally, Castleview Partners LLC increased its holdings in shares of Bristol Myers Squibb by 15.5% during the fourth quarter. Castleview Partners LLC now owns 85,542 shares of the biopharmaceutical company’s stock worth $4,614,000 after buying an additional 11,504 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of several recent analyst reports. Guggenheim reissued a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. UBS Group reissued a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, March 6th. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $59.40 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $58.75 and a 200 day simple moving average of $52.11. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market cap of $120.97 billion, a P/E ratio of 17.22, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.